Loading clinical trials...

Preparation and Feasibility of Exams for Expected Studies | Clinical Trials | Clareo Health

RECRUITINGNA

Preparation and Feasibility of Exams for Expected Studies

Preparation and Feasibility of Exams for Expected Studies (PRELUDE)

NCT05698810•University Hospital, Grenoble

Summary

Feasibility study: the examinations carried out as part of this protocol aim to carry out all the acquisitions and simulations of use, necessary for the development of the clinical research protocols to come to Clinatec (in particular, configuration of the equipment, dimension of the examination time and the size of the cohorts etc ...)

Detailed Description

To ensure the feasibility of a clinical trial, it is necessary to test the parameters as well as the sequence of the different examination times offered to participants. The expected results of this protocol are mainly the dimension of experimental paradigms and the optimization of the clinical management of subjects.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age ⩾ 18 years
•Affiliated to a social security scheme
•Free and informed consent signed

Exclusion Criteria

•Subject in a period of exclusion from another study.
•Subject deprived of liberty by a judicial or administrative decision, or major subject subject to a legal protection measure (guardianship, curatorship and safeguarding of justice) referred to in Articles 1121-6 to 1121-8 of the Public Health Code.
•Subject who would receive more than 4500 euros in compensation because of his participation in other research involving the human person in the 12 months preceding this study.
•Pregnant woman, parturient, nursing mother (Article 1121-5 of the Public Health Code)
•Subject not reachable urgently.

Locations (1)

Clinatec Cea/Chuga

Grenoble, France

Key Dates

Start Date

March 20, 2023

Primary Completion Date

March 20, 2033

Completion Date

March 20, 2033

Last Updated

September 2, 2025

Enrollment

150

ESTIMATED participants

Conditions

Healthy VolunteersParkinson's Disease PatientsPara/Tetraplegic Patients

Interventions

CE marked Medical Device MagnetoEncephaloGraphy (MEG) usability

OTHER

CE marked Medical Device Magnetic Resonance Imaging (MRI) usability

OTHER

CE marked Medical Device ElectroEncephaloGraphy (EEG) usability

OTHER

CE marked Medical Device ElectroCardioGraphy (ECG) usability

OTHER

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGPHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06342713

Healthy ParticipantsHealthy Subjects+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Preparation and Feasibility of Exams for Expected Studies

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

A Study of ENX-104 in Healthy Participants

Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Single-dose,First-in-human of KLA478